hepatitis

Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline
Yahoo Finance
Thu, 05/9/24 - 11:42 am
Bluejay Therapeutics
funding
hepatitis
hepatitis D
Durect fails alcohol-associated hepatitis trial, plans phase 3 anyway as investors scorch stock
Fierce Biotech
Wed, 11/8/23 - 11:33 am
Durect
alcohol-associated hepatitis
hepatitis
clinical trials
Janssen’s newly-merged infectious disease and vaccine unit sees significant pipeline cuts
Fierce Biotech
Thu, 07/20/23 - 10:18 am
JNJ
Janssen
infectious disease
vaccines
hepatitis
HIV
Gilead agrees 41,000 eur hep-C drug price for 12 week treatment
Yahoo/Reuters
Thu, 02/12/15 - 02:06 pm
Gilead Sciences
hepatitis
Europe
Germany
Sovaldi
Gilead Sciences, AbbVie and the End of the Hepatitis-C Trade
Barron's
Sat, 02/7/15 - 10:23 am
Gilead Sciences
AbbVie
hepatitis
hepatitis C
These 2 Biotech Stocks Are Set To Split The $15 Billion Hepatitis C Market
Yahoo/Benzinga
Sat, 12/13/14 - 11:29 am
Gilead Sciences
AbbVie
hepatitis
hepatitis C
After hep C cure, companies target next big liver disease market
Yahoo/Reuters
Sun, 11/9/14 - 09:46 am
hepatitis B
hepatitis
nonalcoholic steatohepatitis
Gilead
Galmed Pharmaceuticals
Raptor Pharmaceuticals
Conatus Pharmaceuticals
ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients
Yahoo/BusinessWire
Sat, 11/8/14 - 11:35 am
daclatasvir
sofosbuvir
hepatitis C
hepatitis
Bristol-Myers Squibb
Politicizing Gilead's Research And Development Costs For Sovaldi Is A Reckless And Dangerous Misadventure
Forbes
Sat, 07/26/14 - 09:56 am
Sovaldi
Gilead Sciences
hepatitis
hepatitis C
3 Breakthrough Drugs Yield 1 Instant Blockbuster
Motley Fool
Sun, 05/25/14 - 10:26 am
Roche
Gazyva
Imbruvica
JNJ
Gilead Sciences
Sovaldi
mantle cell lymphoma
chronic lymphocytic leukemia
leukemia
Biogen
hepatitis
hepatitus C
Why Sovaldi shouldn't cost $84,000
Modern Healthcare
Sun, 05/4/14 - 11:59 am
Sovaldi
hepatitis C
hepatitis
Gilead Sciences
Encouraging Data from Bristol-Myers
Yahoo/Zacks
Sat, 04/12/14 - 10:20 am
Bristol-Myers Squibb
HCV
hepatitis
hepatitis C
daclatasvir
asunaprevir
AbbVie to Present Late-Breaking Results from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis at the 2014 International Liver Congress
Yahoo/PR NewsWire
Sat, 04/12/14 - 10:15 am
hepatitis
hepatitis C
AbbVie
Ribavirin
Encouraging Results on Gilead's Sovaldi
Yahoo/Zacks
Sat, 04/12/14 - 10:13 am
Gilead Sciences
Sovaldi
HCV
hepatitis
hepatitis C
Boehringer Ingelheim reports positive phase 3 SVR12 results in HCV/HIV co-infected patients treated with faldaprevir
Pharmabiz
Sat, 03/8/14 - 10:49 am
SVR12
Boehringer Ingelheim
HCV
HIV
hepatitis
hepatitis C
Gilead: AbbVie No Match For Sovaldi
Barron's
Sat, 02/22/14 - 10:41 am
Gilead Sciences
AbbVie
Sovaldi
hepatitis
hepatitis C
AbbVie Headed to FDA, Clash With Gilead Set
Motley Fool
Sat, 02/1/14 - 10:49 am
AbbVie
Gilead Sciences
ABT-450
hepatitis
hepatitis C
Enanta Pharmaceuticals
Gilead And AbbVie Battle For Top Spot In $20 Billion Hepatitis Drug Market
Seeking Alpha
Sun, 11/24/13 - 12:24 pm
Gilead Sciences
AbbVie
hepatitis
hepatitis C
sofosbuvir
ABT-450
ABT-333
ABT-267
J&J, Medivir Win U.S. FDA Approval for Hepatitis C Pill
Bloomberg
Sat, 11/23/13 - 12:49 pm
JNJ
Medvir
hepatitis C
hepatitis
Olysio
simeprevir
New GT-1b Data from ABT-450 Containing Regimen Being Presented at The Liver Meeting
Yahoo/BusinessWire
Sun, 11/3/13 - 12:08 pm
Enanta Pharmaceuticals
ABT-450
ABT-267
hepatitis
hepatitis C

Pages